Compare Enveric Biosciences Inc (ENVB) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? Enveric Biosciences Inc trades at $1.37 (market cap $5.32M), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $70. The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | VEA | |
|---|---|---|
Market Cap | $5.32M | — |
Sector | Health | — |
52-Week High | $17.40 | $72.39 |
52-Week Low | $1.28 | $56.02 |
Enterprise Value | $408.82K | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
VEA trades at $70.05, down 0.78% today, with technical indicators showing a bullish trend from moving averages while oscillators remain neutral. The ETF maintains strong institutional support with $304 billion in assets under management and a minimal 0.03% expense ratio. Recent news highlights VEA's outperformance versus U.S. benchmarks and competitive positioning against peer international ETFs.
VEA offers exposure to developed international markets at a valuation discount to U.S. equities, with a forward P/E of 17.7x and 3.1% dividend yield. Key risks include currency fluctuations and political developments in constituent countries, but the fund's low-cost structure and diversification benefits support long-term growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
